Our members Know First!! MCKE,QMIN,OCLS,AVID,ENOC,NTRS,

(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS : (OTCBB: MCKE) Morgan Creek Energy Corp., (OTCBB: QMIN) Quest Minerals & Mining Corp., (OTCBB: OCLS) Oculus Innovative Sciences, Inc., (NASDAQ: AVID) Avid Technology, Inc., (NASDAQ: ENOC) EnerNOC, Inc., (OTCBB: NTRS) Northern Trust Corp.

www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com email us!! info@StockMarketingInc.com or call 1-866-583-8960 ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: MCKE - Morgan Creek Energy Corp.) LATEST NEWS!! Morgan Creek Energy Corp. Moves Into Drilling Phase With a Now Increased 70% Majority Working Interest in the North Fork 3-D Prospect DALLAS, Dec 04, 2009 -- Morgan Creek Energy Corp. ("The Company") ("Morgan Creek") (OTC Bulletin Board: MCKE; M6C1-Frankfurt) has received an AFE (Authorization For Expenditure) prepared by Castelli Exploration, Inc. for the drilling and completion costs on its test well on Section 19 of the North Fork 3-D Prospect in Beaver County, Oklahoma.

According to an Amended Agreement signed on December 1, 2009 between Morgan Creek and Bonanza Resources ("Bonanza"), Morgan Creek has an option to acquire a 70% working interest of Bonanza's 85% working interest (a 59.50% net working interest) in the Prospect, up to October 28, 2010. Morgan Creek also has an exclusive right to drill and complete one well on the prospect to earn its 70% working interest in the entire 5,600-acre prospect.

Under the proposed AFE, the projected dry hole and completion expenditures are approximately US $950,000. The AFE is derived from detailed drilling information to target Morrow A and B Sands at approximately 8,700 feet.

Morgan Creek Energy is intending to drill this well in order to prove targets in the Morrow A and B Sands, which have been shown to produce between 300 and 500 barrels of oil per day in this area. In order to develop this target, Morgan Creek and its consultants have used sophisticated 3-D Seismic imaging together with skilled interpretation of the new seismic imaging. Over US $900,000 has been spent on the seismic groundwork used to validate this prospect, and a total of US $1.5 million has been spent on the prospect to date, including acquisition costs.

About Morgan Creek Energy Corp.: Morgan Creek Energy Corp. is a natural resource exploration company engaged in the acquisition and development of strategic oil and natural gas properties. For further information see: www.morgancreekenergy.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: QMIN - Quest Minerals & Mining Corp.) LATEST NEWS!! Quest Minerals & Mining Stays on Par with Production Results for November Gwenco to Report November Coal Revenue of $292,000 on 4,150 Clean Tons of Coal PATERSON, N.J., Dec 3, 2009 -- Quest Minerals & Mining Corp. (Pink Sheets:QMIN) (Frankfurt:QMN9), a Kentucky based operator of energy and mineral related properties, today announced coal revenues of $292,000 for the month of November 2009. Quest's operating subsidiary, Gwenco, Inc., produced and shipped 8,700 gross tons for the month, resulting in sales of 4,150 clean tons of coal.

Eugene Chiaramonte, Jr., President of Quest, stated, "We are pleased to report that Gwenco has managed to maintain its production levels for the month of November, despite the many obstacles it encountered over the last few weeks. Nine days straight of an annual Federal electrical inspection, coupled with extra equipment repairs, caused almost two weeks of downtime for the operation. Even with only half a month of production, we were able to match October's results. This means that the company is still on course to produce 20,000 gross tons per month." "If we are able to continue operating without anymore significant delays or mining stoppages, we should closeout the year on a strong note. The company has already more than doubled its revenues from 2008. So we look forward to seeing the final results." About Quest Minerals & Mining Quest Minerals & Mining Corp., or Quest, acquires and operates energy and mineral related properties in the southeastern part of the United States. Quest focuses its efforts on properties that produce quality compliance blend coal. For more information on Quest Minerals & Mining Corp., please visit our website at www.questmining.net.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: OCLS - Oculus Innovative Sciences, Inc.) LATEST NEWS!! Oculus Innovative Sciences Provides 2010 U.S. Milestones Update Microcyn(R)-Based Product Introductions: PETALUMA, Calif., Dec 03, 2009 --Orthopedic and Surgical -- Microcyn Technology Product Introduction into Orthopedic and Surgical Markets (Jan. 2010) --Negative-Pressure Wound Therapy -- Microcyn Technology Product Introduction as Accessory for Negative-Pressure Wound Therapy Devices (Feb. 2010) --Microcyn Skin and Wound HydroGel - Dermatology Indications - Microcyn Technology HydroGel Product Introduction into Dermatology Market (Q2 2010) --Microcyn-Based Products FDA Clearances: --Upper Respiratory - Expecting FDA Clearance for Allergy Block HydroGel (Q3 2010) --Second Dermatology Product -- Expecting FDA Clearance for Atopic Dermatitis HydroGel (Q3 2010) --Oculus Partner Updates: --Animal Health - Vetericyn(TM) Animal Products Introduced into Canine Market through Dog Whisperer, Cesar Millan (Current) --Professional Oral Care -- Microcyn Technology Products FDA Cleared and Introduced into Oral Biofilm and Mucoprotectant Market (Q2/Q3 2010) Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, initially intended to treat chronic and acute wounds, today unveiled an expanded regulatory/commercial pipeline for its Microcyn-based products as preparation for the company's CEO and founder, Hoji Alimi, to provide even greater detail at the OneMedForum on January 12, 2010 in San Francisco.

"We see 2010 as being a breakout year in terms of U.S. product regulatory clearances, new product introductions, revenue growth and partner activities. While we're unable to control the timing of the FDA review process, we believe these anticipated marketing clearances will be transformative, creating added revenue streams that will help get us to revenues of greater than $45 million to $60 million with operating profitability of 20% by 2013," said Hoji Alimi, Oculus CEO and founder. "Based upon shareholder feedback, we have decided to provide greater transparency in terms of identifying the 2010 milestones by which we will measure our success over the coming year. I think it important that investors be able to see the extensive efforts being put forth by Oculus' R&D and marketing teams, as well as our U.S. partners, to move beyond the existing product portfolio and generate new Microcyn-based products for applications including orthopedic and surgical irrigation, an advanced solution that is complementary to negative-pressure wound therapy devices, oral care, dermatology treatments and allergy relief." United States Product Introductions: Orthopedic and Surgical Irrigation - (Introduction: Jan. 2010) Packaged in a sterile, spikeable bottle that is ideal for use in orthopedic and surgical applications, Oculus will introduce Microcyn OSID in January of 2010. Oculus will leverage its 30-second kill times in solution against dangerous pathogens such as MRSA and VRE. Unlike current standards of care, Microcyn OSID is non-foaming, non-sensitizing, and based upon evidence, does not appear to facilitate resistant strains of bacteria.

Adam Landsman, DPM, Ph.D. and assistant professor of surgery at Harvard Medical School in Boston, who was lead investigator in a Phase II trial in which the Microcyn Technology was used to treat mildly infected diabetic foot ulcers in 2007, stated: "The current standard for surgical wound cleansing and irrigation involves the use of products that do not kill the MRSA infection in-vitro. This is important in light of the skyrocketing proliferation of these dangerous bacteria as well as the evolving 'super bug' mutations. Microcyn is also highly attractive since it does not produce foam, which hampers visualization of the wound. And finally, with the health community so vitally focused on cost savings, the Microcyn OSID will actually cost less than the current combination of saline and bacitracin." For years, the standard of care for surgical irrigation was saline infused with bacitracin, an antibiotic first discovered in 1945. According to the journal Orthopedics (2008; 31:37), due to resulting resistance, bacitracin is no longer considered effective for MRSA decolonization. Surgical irrigation and debridement remains the standard of care for removal of necrotic tissue and is used when the tissue removal needs are extensive, or when the patient has a serious infection associated with the surgical wound site.

According to Medtech Insight, a Division of Windhover Information, in 2004 there were approximately 36 million surgical wounds and nine million open trauma wounds in the United States. Initially, Microcyn OSID(TM) will be marketed by the Advocos sales team that is currently selling the professional formulations of the Microcyn-based wound care products.

Accessory for Negative-Pressure Wound Therapy (NPWT) Devices - (Introduction: Jan. 2010) According to U.S. Markets for Current and Emerging Wound Closure Technologies, a report published in April 2009 by Medtech Insight, 2009 sales of negative-pressure wound therapy products will total approximately $1.1 billion. Oculus' new Microcyn NPWT solution can be used in conjunction with the NPWT devices from Kinetic Concepts Inc., Smith and Nephew, ConvaTec, Innovative Therapies, Medela, NovaSpine and Boehringer Wound Systems.

Microcyn Skin and Wound HydroGel - Dermatology Indications - (FDA Regulatory Clearance and Introduction: Q2 2010) Oculus has filed a 510(k) application with the FDA to secure marketing clearances of the Microcyn HydroGel product for dermatological uses. This clearance is expected in the first half of 2010. The indication under review proposes that the HydroGel, under the supervision of a medical professional, be used for treatment of first- and second-degree burns (including sunburns), radiation dermatitis, itching, skin conditions associated with periostomy care, skin irritation associated with tattooing procedures, irritation and pain following skin laser resurfacing treatment, dermabrasion therapy and chemical peels.

United States Regulatory Clearances: Allergy Block HydroGel OTC - (FDA Regulatory Clearance: Q3 2010) Microcyn Allergy Block HydroGel(TM) is designed as a self-contained package of disposable applicators and an anti-allergy formulation of Microcyn HydroGel to be applied to the interior of the nasal cavities for relief from allergy symptoms including allergic rhinitis.

An allergy is an overreaction of the immune system to a substance that's harmless to most people. But in someone with an allergy, the body's immune system treats the substance (called an allergen) as an invader and reacts inappropriately, resulting in symptoms that can be anywhere from annoying to possibly harmful to the person. In an attempt to protect the body, the immune system of the allergic person produces antibodies called immunoglobulin E (IgE). Those antibodies then cause mast cells to release chemicals, including histamine, into the bloodstream to defend against the allergen.

There were more than 12 million physician office visits because of allergic rhinitis in 2006, affecting between 10% and 30% of all adults and as many as 40% of children. From 2000 to 2005, the cost of treating allergic rhinitis almost doubled from $6.1 billion (in 2005 dollars) to $11.2 billion. More than half of that was spent on prescription medications.

Atopic Dermatitis HydroGel Rx - (FDA Regulatory Clearance: Q3 2010) An FDA clearance for a prescription Microcyn AD HydroGel(TM) specially formulated for the treatment of atopic dermatitis is expected in Q3 2010, after which time it will be marketed to the nearly 16,000 U.S. dermatologists.

Atopic dermatitis is a common and chronic inflammatory skin disease marked by red, itchy rashes. It has been increasing in prevalence over the past two decades and affects a disproportionate number of children. According to current estimates, approximately 15 percent to 20 percent of children in the United States and other industrialized countries around the world develop atopic dermatitis in the first few years of life. By comparison, only an estimated three percent to five percent of adults have an active form of the condition.

The skin of a patient with atopic dermatitis reacts abnormally and easily to irritants, food, and environmental allergens and becomes red, flaky and very itchy. It also becomes vulnerable to surface infections caused by bacteria. The skin on the flexural surfaces of the joints (for example inner sides of elbows and knees) are the most commonly affected regions in people. Although there is no cure for atopic eczema, and its cause is not well understood, it can be treated in the short term through a combination of prevention (learning what triggers the allergic reactions) and drug therapy.

According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases, in a recent analysis of the costs associated with atopic dermatitis in the United States, researchers reviewed studies evaluating both direct costs (doctor visits, hospitalizations, and medicine) and indirect costs (over-the-counter remedies, lubricants, and days lost from work). They found that direct costs totaled about 25 percent, and indirect costs totaled about 75 percent of costs. Per patient, the costs averaged about $600 per year. On the whole, direct costs alone may exceed $3 billion per year.

Oculus Partner Updates: Vetericyn(TM) Animal Healthcare Products - (Current) Following the successful introduction via a national advertising campaign of the Vetericyn products into the equine market by Oculus' partner, Innovacyn, Vetericyn products for the canine market are now being promoted via the world-famous Cesar Millan and his Dog Whisperer(R) franchise.

Oral Antibiofilm and Mucoprotectant - (FDA Regulatory Clearance and Introduction: Q2/Q3 2010) As announced in July 2009, Oculus licensed the Microcyn Technology to OroScience, Inc. for the professional oral care markets in the United States, Canada and Europe. OroScience anticipates initially introducing two Microcyn-based products, namely Periocyn(TM) Antitbiofilm Rinse for the treatment of gingivitis and Periocyn(TM) Mucoprotectant for the treatment of oral mucositis. OroScience believes FDA clearances to market these products are expected by early second quarter 2010.

Gingivitis is an inflammation of the gingival (gums) characterized by a change in color from normal pink to red, with swelling, bleeding, and often sensitivity and tenderness. Gingivitis is caused by bacteria in the biofilm or dental plaque that forms on oral surfaces. If left untreated, gingivitis can progress to more severe forms of periodontal disease and result in deep pockets between the teeth and gums and loss of bone around teeth and eventual loss of teeth as well as halitosis (bad breath). In a 1999 study reported by the Centers for Disease Control and Prevention, 50.3% of the U.S. population aged 30 years or older were afflicted with gingivitis. Early and sustained treatment of gingivitis is an important factor in preventing the progression of gingivitis to more severe forms of periodontal disease.

Oral mucositis (OM) is a common, painful, and often debilitating side effect of cancer therapy such as chemotherapy and radiotherapy. OM is estimated to affect more than 800,000 cancer patients each year in the EU and United States. OM affects approximately 40% of cancer patients who receive chemotherapy, more than 70% of those undergoing conditioning therapy for bone marrow transplantation, and patients receiving radiation therapy for head and neck cancer. The economic impact of mucositis can be significant, as the need for prolonged hospital stays, nutritional therapy and treatments for pain and infection can drive up the costs of therapy.

These professional Microcyn-based oral care products, along with future applications, will be distributed by OroScience beginning in mid-2010 via a large global dental distributor. Oculus retains the right to either market or license the over-the-counter formulations globally.

OneMedForum 2010 Update: Hoji Alimi, Oculus CEO and founder, will provide a regulatory and commercialization update relative to the U.S. pipeline as well as advances being realized in the international markets during his 10:45 am, January 12, 2010 OneMedForum presentation at the Sir Francis Drake Hotel in San Francisco.

About Oculus Innovative Sciences Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which includes new formulations designed to significantly reduce the need for antibiotics as it reduces infections. The Microcyn Technology platform features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country specific regulatory clearances and approvals. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increase blood flow to the wound site, reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with operations in Latin America. More information can be found at www.oculusis.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: AVID - Avid Technology, Inc.) LATEST NEWS!! Avid to Present at Brigantine Advisors' Tech Trends in 2010 Conference TEWKSBURY, MA, Dec 04, 2009 -- Avid(R) (NASDAQ: AVID) today announced that Ken Sexton, executive vice president, CFO and CAO, will present on the company's business at Brigantine Advisors' Tech Trends in 2010 Conference on Thursday, December 10, 2009 at 11:00 a.m. EST. The event will be held at Bloomberg Global Headquarters in New York City. An on-demand audio webcast of the presentation will be accessible via Avid's Web site during the conference and for a limited period following the conference. To listen, please visit http://ir.avid.com/.

About Avid Avid creates the digital audio and video technology used to make the most listened to, most watched and most loved media in the world -- from the most prestigious and award-winning feature films, music recordings, television shows, live concert tours and news broadcasts, to music and movies made at home. Some of Avid's most influential and pioneering solutions include Media Composer(R), Pro Tools(R), Avid Unity(TM), Interplay(R), Oxygen 8, Sibelius(R) and Pinnacle Studio(TM). For more information about Avid solutions and services, visit www.avid.com, del.icio.us, Flickr, Twitter and YouTube; connect with Avid on Facebook; or subscribe to Avid Industry Buzz.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: ENOC - EnerNOC, Inc.) LATEST NEWS!! EnerNOC Customer Johnson & Johnson Wins Platts Global Energy Award J&J Wins Energy Efficiency Program of the Year Award BOSTON, Dec 4, 2009 -- EnerNOC, Inc. (Nasdaq:ENOC), a leading provider of clean and intelligent energy solutions, today announced that Johnson & Johnson, an EnerNOC customer, was honored with a 2009 Platts Global Energy Award in the "Energy Efficiency Program of the Year" category. EnerNOC nominated Johnson & Johnson in recognition of its efforts to consistently set the highest standard of excellence in energy management and in honor of its efforts to use energy more efficiently, particularly during times of peak demand. J&J currently contributes more than seven megawatts of demand response capacity across multiple sites in North America through participation in EnerNOC's network.

"Johnson & Johnson is a role model for the modern corporation in terms of its sustainability and energy management efforts, and we're proud that EnerNOC demand response is part of its award-winning, holistic energy management strategy," said Tim Healy, EnerNOC's Chairman and CEO. "EnerNOC understands that a comprehensive approach to energy management is key to any successful energy efficiency and carbon reduction effort. We're committed to providing the country's most well-run businesses, like Johnson & Johnson, the tools they need to unlock the value of energy management." The "Energy Efficiency Program of the Year" award recognizes a long-term, systematic commitment to energy efficiency, as opposed to a "flash-in-the-pan" project. EnerNOC's demand response application is a component of Johnson & Johnson's holistic approach to an energy management program that has a measurable impact on the environment and Johnson & Johnson's bottom line. Other elements of the program include utilizing the largest hybrid fleet in the U.S. (over 2,100 hybrid vehicles), sourcing 34 percent of energy from renewable resources, and serving on the Carbon Disclosure Project's Supply Chain Leadership Council and the U.S. Climate Action Partnership. The company also has significant energy efficiency goals, such as reducing its fleet's carbon emissions by 30 percent, achieving a 7 percent absolute reduction in CO2, and further reducing water use and waste generation at its sites.

Recipients of Platts Global Energy Awards were honored on December 3, 2009 at an awards ceremony in New York City.

For information about joining EnerNOC's demand response network, please visit www.enernoc.com/get-started or email info@enernoc.com.

About EnerNOC EnerNOC, Inc. is a leading provider of clean and intelligent energy solutions, which include demand response services, energy efficiency, or monitoring-based commissioning services, energy procurement services, and emissions tracking and trading services. These solutions help optimize the balance of electric supply and demand, provide cost-efficient alternatives to traditional power generation, transmission, and distribution resources, and drive significant cost-savings for its customers. The Company uses its Network Operations Center, or NOC, and PowerTrak(R) enterprise software platform to remotely manage and reduce electricity consumption across a growing network of commercial, institutional, and industrial customer sites, making demand response capacity available to grid operators and utilities on demand while helping end-users of electricity achieve energy savings, environmental benefits, and improved financial results. For more information visit www.enernoc.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------ (OTCBB: NTRS - Northern Trust Corp.) LATEST NEWS!! Northern Trust Selects Firms for Emerging Broker Program CHICAGO, Dec 04, 2009 -- Northern Trust announced today that its asset management arm, Northern Trust Global Investments (NTGI), has selected seven emerging and minority/women-owned broker-dealers for its list of preferred equity trading partners.

The equity trading firms, which met selection criteria including execution capabilities, technology platforms and capital commitment, are: -- M.R. Beal and Company, Chicago, Ill.

-- Blaylock Robert Van Securities, LLC, Oakland, Calif.

-- Cabrera Capital Markets, LLC, Chicago -- Guzman & Company, Coral Gables, Fla.

-- Loop Capital Markets, Chicago, Ill.

-- M. Ramsey King Securities, Inc., Burr Ridge, Ill.

-- Samuel A Ramirez & Company, Inc., New York, N.Y.

"We are pleased to maintain relationships with seven broker-dealers that have the strength and expertise to become strategic trading partners with Northern Trust," said Lyle Logan, executive vice president and managing director of client servicing and sales at NTGI. "In addition to best execution in particular markets, these firms demonstrate a commitment to compliance and risk management that is important to Northern Trust and our clients." Equity trading partners were selected by NTGI executives from a group of 36 broker-dealers that responded to a request for information. Northern Trust went through a similar process in 2007, and the firms selected then were invited to rebid. Because fixed-income requires a larger universe of trading partners to achieve liquidity and best pricing, NTGI does not limit the number of firms it considers for fixed income trading.

Northern Trust's diversity commitment also includes its Emerging Managers Practice, which invests more than $4 billion across 46 investment strategies and 42 emerging-minority-owned investment management firms through manager-of-manager programs. In corporate procurement, the Supplier Diversity office seeks to ensure that Northern Trust provides opportunities for minority, women and disabled business owners and expands the use of diverse firms in the corporate supply chain.

Northern Trust is committed to deepening its strategic relationships with emerging and minority/women-owned broker-dealers. In 2008, Northern Trust traded in excess of $40 billion worth of equity and fixed-income securities with broker-dealers in the program, up from $30 billion in 2006.

Northern Trust Global Investments (NTGI) is the multi-asset class investment management business of Northern Trust Corporation. NTGI comprises Northern Trust Investments, N.A., Northern Trust Global Investments Limited, Northern Trust Global Investments Japan, K.K., the investment advisor division of The Northern Trust Company and Northern Trust Global Advisors and its subsidiaries.

About Northern Trust Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of investment management, asset and fund administration, banking solutions and fiduciary services for corporations, institutions and affluent individuals worldwide. Northern Trust, a financial holding company based in Chicago, has offices in 18 U.S. states and 16 international locations in North America, Europe, the Middle East and the Asia-Pacific region. As of September 30, 2009, Northern Trust had assets under custody of US$3.6 trillion, and assets under investment management of US$611 billion. For 120 years, Northern Trust has earned distinction as an industry leader in combining exceptional service and expertise with innovative products and technology. For more information, visit www.northerntrust.com ------------------------------------------------------------------------------------------------------------------------------------------------------------ About StockMarketingInc.com StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

((Comments on this story may be sent to info@m2.com)) (c) 2009 M2 COMMUNICATIONS

[ Back To Homepage ]

| More

The World's Largest Communications And Technology Community

Technology Marketing Corporation,
800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800; Fx: 203-866-3326
General comments: tmc@tmcnet.com. Comments about this site: webmaster@tmcnet.com.

» About » Contact » Advertise